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Abstract
While the deciphering of basic sequence information on a genomic scale is yielding
complete genomic sequences in ever-shorter intervals, experimental procedures for
elucidating the cellular effects and consequences of the DNA-encoded information
become critical for further analyses. In recent years, DNA microarray technology
has emerged as a prime candidate for the performance of many such functional
assays. Technically, array technology has come a long way since its conception some
15 years ago, initially designed as a means for large-scale mapping and sequencing.
The basic arrangement, however, could be adapted readily to serve eventually as an
analytical tool in a large variety of applications. On their own or in combination
with other methods, microarrays open up many new avenues of functional analysis.
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In the DKFZ Division of Functional Genome Anal-
ysis, we are developing technologies for the iden-
tiﬁcation, description and evaluation of cellular
functions and their regulation, by producing and
processing biological information on a genomic
scale. One emphasis in our effort is work on DNA,
protein and peptide microarrays. Many chemical
and biophysical issues are being addressed in an
attempt to understand the underlying procedural
aspects, thereby eventually establishing superior
analysis procedures. Based on technical advances,
the resulting methods are immediately put to the
test in relevant, biologically-driven studies on var-
ious organisms. Concerning the analysis of human
material, systems are being developed toward early
diagnosis, prognosis and evaluation of the success
of disease treatment, with an emphasis on cancer.
Determination of base variations
Genotyping has developed enormously with the
advent of single nucleotide polymorphisms (SNPs).
Not only are there very many of them but they can
also be assayed in a parallel format. Nevertheless,
the capacity for large-scale analyses is still critical
to many potential applications. Also, the selec-
tion of informative SNPs is a limiting aspect.
We are performing SNP-typing experiments in
molecular epidemiological studies, for example. In
collaboration with Alexandra Nieters and Niko-
laus Becker (DKFZ, Heidelberg), a microarray has
been established for the analysis of SNPs asso-
ciated with the existence of lymphoid neoplasms
(Figure 1). The initial aim of this project is a
combination of epidemiological data obtained from
a case-control study of about 600 patients and
600 matched unaffected individuals with molec-
ular information on some 100 appropriate SNPs.
This study is part of a much wider effort coordi-
nated by an international network called Interlymph
(http://dceg2.cancer.gov/newsletter/News0303.
html#interlymph), in which some 20000 case and
control samples await genetic analysis. We are
using the Geniom platform of febit (Mannheim,
Germany) for the generation and use of complex
oligonucleotide arrays. The device currently per-
mits in situ synthesis of microarrays that contain up
to 64000 different oligonucleotides. All of the steps
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Figure 1. SNP-typing on an oligonucleotide microarray. The microarray was produced using the Geniom unit from febit
(Mannheim, Germany). The oligonucleotides had a length of 20 nt. Only a portion of the entire microarray is shown.
A simultaneous hybridization of PCR products that represented 95 SNPs yielded the binding pattern that is presented.
Examples of heterozygous and homozygous polymorphisms are highlighted, which were also conﬁrmed by enzymatic
sequencing
necessary for in situ oligomer synthesis (starting
from an empty cartridge), sample hybridization and
detection are carried out within the device and on
site. Any combination of oligonucleotide sequences
can be generated on the microarray, based on indi-
vidual data ﬁles created or assembled by the user.
Therefore, empirical results from earlier hybridiza-
tions can immediately be applied to the improve-
ment of the next microarray. In another collabora-
tive effort (with Ethel de Villiers, also at DKFZ),
the system is used to establish an array-based
assay for the identiﬁcation and discrimination of
all Human Papilloma Virus (HPV) types by virtue
of differences in their sequence. Some HPV types
are considered to be necessary aetiological fac-
tors for the development of cervical cancer, while
others are mainly associated with benign lesions.
A third form of analysis — done in collaboration
with Frank Lyko (DKFZ) and the company Epige-
nomics (Berlin, Germany) — aims at the elucida-
tion of the methylation status of genomic DNA.
For this kind of study, genomic DNA is treated
with bisulphite. While methylated cytosine remains
unaffected, unmethylated cytosine is chemically
transformed into uracil, and subsequently thymi-
dine upon PCR ampliﬁcation. This transformation
can be assayed as a polymorphism at the respective
site by comparing DNA before and after bisulphite
treatment [1].
With the availability of photolabile 3-O-[2(2-
nitrophenyl)propoxycarbonyl]-protected 5-phos-
phoramidites [2], an alternative mode of light-
directed production of oligonucleotide arrays
became possible. Because of the characteristics of
these building blocks, light-controlled in situ DNA
synthesis occurs in the 5–3 direction, conform-
ing to the orientation of enzymatic synthesis. Thus,
the 3-termini of the eventual oligonucleotides can
act as substrates for on-chip polymerase reactions.
The production of such oligonucleotide arrays adds
new procedural avenues to DNA microarrays. With
respect to genotyping, complexity of the samples,
and thus throughput, can be increased substan-
tially [3].
Even further advances could be expected by
using a process that circumvents the fact that the
DNA samples to be studied usually require (PCR)
ampliﬁcation and (ﬂuorescence) labelling prior to
analysis. The structural difference between peptide
nucleic acid (PNA) — used as probe molecule
on the array — and a DNA target permits direct
detection of a binding event. Upon hybridization
of a nucleic acid sample to a PNA array, the
phosphates of the DNA/RNA can be utilized as an
intrinsic label for detection by secondary ion mass
spectrometry (SIMS); PNA molecules are lacking
phosphate groups entirely. In collaboration with
Heinrich Arlinghaus (University of M¨ unster), we
established the basic processes for analysing DNA
by such means [4,5].
Transcriptional proﬁling
For understanding the complex regulative mecha-
nisms and investigating the management of cellular
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control, a parallel determination of the expression
of all of the genes of an organism or tissue
is indispensable. One of many practical applica-
tions pursued by us is the analysis of pancreatic
tumourigenesis. Pancreatic cancer is the ﬁfth most
common cause of cancer-related deaths in indus-
trialized countries, with a dismal prognosis, an
increasing incidence and no, or only rather inef-
fective, means of treatment. The development of
new treatment modalities and diagnostic and pre-
ventive approaches requires an understanding of
the molecular mechanisms of tumourigenesis in the
pancreas. In collaboration with Thomas Gress (Uni-
versity of Ulm, Germany) and Helmut Friess (Uni-
versity of Heidelberg, Germany), we are analysing
a set of genes known to be speciﬁcally differen-
tially transcribed in pancreatic tumours in clinical
samples. Towards the objective of performing diag-
nosis — on the basis of which eventually prognosis
might be possible — or for the identiﬁcation of
potential target molecules, the selection of appro-
priate probes and the availability of good-quality
tissue samples are essential, but nevertheless only
initial, steps. Just as important is data integration,
since tying connections between molecular and
clinical data makes subsequent interpretation more
likely to succeed. This process requires a modu-
lar data warehouse concept, in which experimental
data, such as raw signal intensities or gene anno-
tations, are stored in combination with the clini-
cal information available on the samples/patients
in a pre-deﬁned and catalogued vocabulary ([6,7];
www.dkfz-heidelberg.de/funct genome/index.
html#mchips; currently a total of 4755 hybridiza-
tion experiments are stored). Then, statistical algo-
rithms can be utilized for the identiﬁcation of
molecular factors that are characteristic for a cer-
tain subgroup of samples, and thus patients, for
example (Figure 2). In addition, the association
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Figure 2. Biplot presentation of the results of a correspondence analysis [7]. Transcriptional proﬁling data were generated
from normal pancreatic tissues, material from patients with chronic pancreatitis, and cancer patients. The various samples
could be discriminated easily, forming distinct clusters that — expectedly — have a very high correlation with the origin of
the various samples
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of groups of genes with a certain type of dis-
ease progression, or their — potentially even indi-
rect — relevance to a particular pathway, may be
identiﬁed in a more automated fashion.
For many applications, the availability of micro-
arrays that represent the entire genome rather than
the coding sequences only would be beneﬁcial.
Such an array would, by deﬁnition, contain all
of the genes of the given organism, irrespective
of the status and quality of sequence annotation.
More importantly, all genomic regions, including
the important regulatory portions, for example,
would become accessible to analysis. Along these
lines, we have produced a minimal tiling path
of fragments from the shotgun clones used for
sequencing the genome of Pseudomonas putida [8],
for instance. Further work in this direction is in
progress.
Protein expression
While two-dimensional gel electrophoresis does
provide a powerful technique for the analysis of
at least a large number of proteins of an organ-
ism or tissue, many other powerful methods are
nevertheless prerequisite to approaching the world
of protein analysis in a manner similar to what
is already possible for studies at the level of
nucleic acids [9,10]. However, the biochemical
diversity and the sheer number of proteins are
such that an equivalent analysis is much more
complex and thus difﬁcult to accomplish. Perform-
ing microarray immunoassays, for instance, repre-
sents a challenge even at the level of preparing
a working microarray surface. We compared dif-
ferent strategies for producing antibody microar-
rays on glass slides, analysing the effect of mul-
tiple factors — the modiﬁcation of the glass sur-
face, the kind and length of cross-linkers, the
composition and pH of the spotting buffer, block-
ing reagents, antibody concentration and storage
procedures — on array performance. Data from
nearly 1000 slides were analysed for this evalu-
ation, and to establish appropriate assay conditions
[11,12].
Initial experiments aimed at an actual expres-
sion proﬁling of cancer tissues are under way.
On the basis of transcriptional proﬁling exper-
iments using a microarray that contains thou-
sands of cancer-associated genes, several hun-
dred differentially transcribed genes of interest
were selected. Antibodies for their respective pro-
teins were generated in cooperation with the com-
pany Eurogentec (Seraing, Belgium) by synthe-
sizing sequence-speciﬁc peptides, which in turn
were used for immunization of rabbits. This pro-
cess provided us with an initial set of antibodies
that are being used as probes on antibody microar-
rays. For more global studies, other selection meth-
ods and antibodies that originate from recombi-
nant antibody libraries will be required. Compar-
ative analyses of protein expression and transcrip-
tional changes observed in the same tissues are
under way.
Conclusion
Although microarray technology has grown from
infancy into a lively teenager, one should keep
in mind nevertheless that there is much more
to come from this type of analysis and that the
technique’s current behaviour is not always at
its best. Nevertheless, its contribution to func-
tionally oriented research is already tremendous,
although still dwarfed by the potential that can
be tapped into. The range in the status of cur-
rent developments is wide. While initial assays are
already entering the diagnostic market, new areas
of application are still being developed, and await
exploitation.
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